David Zebrowski

David is the Founder and CEO of GenKardia, a biotechnology company developing siRNA-based therapeutics for heart failure. Prior to founding GenKardia, David received his B.Sc. from Carnegie Mellon University and his Ph.D. from Rutgers Medical School, followed by postdoctoral fellowships at Harvard Medical School and Boston Children’s Hospital in the United States, and the Max Planck Institute of Heart and Lung Research in Germany. David subsequently transitioned into pharmaceutical R&D, working in early-stage target discovery and therapeutic development for heart failure at AstraZeneca and Novo Nordisk. Driven by a desire to accelerate the translation of novel scientific discoveries into therapies, he then moved back into academia as a Professor at The Chinese University of Hong Kong / Hong Kong Children’s Hospital, where he continued to develop and test innovative therapeutic concepts. In 2023, David moved back to the United States to found GenKardia.